GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Shiller PE Ratio

CPRX (Catalyst Pharmaceuticals) Shiller PE Ratio : 58.06 (As of Jul. 23, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Shiller PE Ratio?

As of today (2025-07-23), Catalyst Pharmaceuticals's current share price is $20.90. Catalyst Pharmaceuticals's E10 for the quarter that ended in Mar. 2025 was $0.36. Catalyst Pharmaceuticals's Shiller PE Ratio for today is 58.06.

The historical rank and industry rank for Catalyst Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

CPRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 57.74   Med: 102.79   Max: 950.5
Current: 58.06

During the past years, Catalyst Pharmaceuticals's highest Shiller PE Ratio was 950.50. The lowest was 57.74. And the median was 102.79.

CPRX's Shiller PE Ratio is ranked worse than
73.51% of 151 companies
in the Biotechnology industry
Industry Median: 38.2 vs CPRX: 58.06

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was $0.450. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.36 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalyst Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Catalyst Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Shiller PE Ratio Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 482.32 122.70 68.58

Catalyst Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.02 74.35 78.47 68.58 66.83

Competitive Comparison of Catalyst Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Catalyst Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Catalyst Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=20.90/0.36
=58.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Catalyst Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.45/134.9266*134.9266
=0.450

Current CPI (Mar. 2025) = 134.9266.

Catalyst Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -0.060 100.684 -0.080
201509 -0.050 100.392 -0.067
201512 -0.070 99.792 -0.095
201603 -0.070 100.470 -0.094
201606 -0.060 101.688 -0.080
201609 -0.050 101.861 -0.066
201612 -0.050 101.863 -0.066
201703 -0.060 102.862 -0.079
201706 -0.050 103.349 -0.065
201709 -0.050 104.136 -0.065
201712 -0.060 104.011 -0.078
201803 -0.060 105.290 -0.077
201806 -0.060 106.317 -0.076
201809 -0.080 106.507 -0.101
201812 -0.140 105.998 -0.178
201903 -0.010 107.251 -0.013
201906 0.100 108.070 0.125
201909 0.130 108.329 0.162
201912 0.070 108.420 0.087
202003 0.100 108.902 0.124
202006 0.090 108.767 0.112
202009 0.410 109.815 0.504
202012 0.110 109.897 0.135
202103 0.070 111.754 0.085
202106 0.110 114.631 0.129
202109 0.100 115.734 0.117
202112 0.090 117.630 0.103
202203 0.120 121.301 0.133
202206 0.200 125.017 0.216
202209 0.200 125.227 0.215
202212 0.220 125.222 0.237
202303 0.260 127.348 0.275
202306 0.330 128.729 0.346
202309 -0.290 129.860 -0.301
202312 0.310 129.419 0.323
202403 0.190 131.776 0.195
202406 0.330 132.554 0.336
202409 0.350 133.029 0.355
202412 0.440 133.157 0.446
202503 0.450 134.927 0.450

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalyst Pharmaceuticals  (NAS:CPRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Catalyst Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Executives
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard J Daly director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286